Lepu Biopharma Co., Ltd. has strategically built our pipeline with a range of oncology products, including ADCs, immunotherapies and oncolytic virus drugs. We have (i) one clinical/commercialization-stage drug candidate; (ii) seven clinical stage drug candidates, including one co-developed through a joint venture; and (iii) three clinical stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the seven clinical-stage drug candidates, six are targeted therapeutics and one is an immunotherapeutic, which is an oncolytic virus drug. We have initiated multiple clinical trials, amongst which one is ongoing in the U.S., and five have entered the stage of registrational trials in the PRC.